| Similar Articles |
|---|
 |
The Motley Fool
August 10, 2007
Brian Lawler |
ViroPharma Whacked by Data Shares of ViroPharma fall after safety issues come to light with one of its drugs. A phase 2 study of their hepatitis C antiviral medication has been halted, with only a slim chance of starting up again.   |
The Motley Fool
September 27, 2007
Brian Lawler |
ViroPharma's Good Bad News The prospects for ViroPharma's HCV-796 darkened significantly after the company reported troubling clinical results, however, there's still hope for the compound. Investors, take note. |
The Motley Fool
December 16, 2011
Brian Orelli |
Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function. |
The Motley Fool
October 31, 2007
Brian Lawler |
The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note. |
The Motley Fool
April 29, 2008
Brian Lawler |
So Pharmasset, So Good Early data hints at a promising hepatitis C treatment. |
The Motley Fool
June 13, 2007
Brian Lawler |
ViroPharma Is on Its Way ViroPharma completes preliminary enrollment in a study of one of its drug candidates. Investors, take note. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
April 3, 2008
Brian Lawler |
Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug. |
The Motley Fool
March 31, 2008
Brian Lawler |
A Little Funding for Pharmasset Development-stage drugmaker Pharmasset may be on to something with its hepatitis C compounds. |
The Motley Fool
October 19, 2007
Brian Lawler |
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down. |
The Motley Fool
April 30, 2008
Brian Lawler |
Idenix Aims for a Comeback This drugmaker may be down, but it's not yet out. |
The Motley Fool
August 6, 2007
Brian Lawler |
Don't Discount ViroPharma The exciting biopharma announces its second-quarter financial results. Considering that its lead drug is highly profitable and has two strong pipeline candidates in development, shares of ViroPharma don't look expensive. |
The Motley Fool
May 17, 2010
Luke Timmerman |
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. |
The Motley Fool
November 8, 2007
Brian Lawler |
Idenix Reels Itself In The small-cap drug developer cuts expenditures in the third quarter when sales of their hepatitis treatment don't materialize as quickly as hoped. Investors, take note. |
The Motley Fool
May 23, 2008
Brian Lawler |
Vertex's Lead Cut Down Schering-Plough is moving forward with its antiviral hepatitis C drug even faster than expected, much to Vertex's dismay. |
The Motley Fool
August 5, 2010
Brian Orelli |
Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still. |
The Motley Fool
February 28, 2008
Brian Lawler |
ViroPharma in Check Sales of its antibiotic are slowing down, but there is a promising drug in its pipeline. |
Chemistry World
April 21, 2010
Sarah Houlton |
Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
September 26, 2008
Brian Lawler |
Less Is More for Vertex The company's potential hepatitis C compound proves effective with fewer dosages. |
The Motley Fool
January 8, 2008
Brian Lawler |
InterMune Goes Step by Step The company updates investors on the progress of its lead drug for hepatitis C. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
February 11, 2010
Brian Orelli |
A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects. |
The Motley Fool
October 24, 2007
Brian Lawler |
Pharmasset on the Fast Track Hepatitis and HIV drug developer announced that its lead antihepatitis C compound has received fast-track status from the FDA. The decision is not fantastic news, but it could help. Investors, take note. |
The Motley Fool
April 25, 2011
Luke Timmerman |
Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it? |
The Motley Fool
November 3, 2006
Brian Lawler |
Nothing's Wrong With ViroPharma Despite potential generic competition on the horizon, the company is going strong. Vancocin's fate will determine how well shares of ViroPharma perform in the near future. |
The Motley Fool
September 28, 2007
Brian Orelli |
Idenix Axes Ailing Initiatives The small drug developer drops its hepatitis B program, deciding instead to focus on its HCV and HIV drug development. Investors, take note. |
The Motley Fool
June 15, 2007
Brian Lawler |
Idenix Gets Knocked Shares of Idenix drop slightly after the drug developer released clinical trial results this week. |
The Motley Fool
October 30, 2006
Brian Lawler |
InterMune Plays "Let's Make a Deal" The biopharmaceutical 's deal with Roche could mean stiff competition for rival Vertex. Investors, take note. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
August 31, 2007
Brian Lawler |
4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals. |
The Motley Fool
April 19, 2005
Charly Travers |
A Rising Star in Biotech Idenix is following a proven path to success: novel drug development. This is one biotech to keep on your watch list for the next year. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
September 27, 2006
Brian Lawler |
One Step Forward for InterMune The company's lead drug will enter phase 1 trials, bringing potential good fortune to investors. |
The Motley Fool
July 24, 2007
Brian Lawler |
Discounting InterMune Shares of InterMune fall after analyst worries about one of its drugs. Investors looking to buy into the next blockbuster class of hepatitis C treatments on the cheap just got their chance. |
The Motley Fool
June 27, 2008
Brian Lawler |
Difficult Obstacles for SciClone With all the new technologies and discoveries, some drugmakers are undoubtedly going to be left in the dust. SciClone Pharmaceuticals, with its lead drug Zadaxin, might be one such drugmaker. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
January 17, 2008
Brian Lawler |
The Good Times Roll for Pharmasset Shares ride high after the company releases positive clinical trial data. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
July 16, 2007
Brian Lawler |
Idenix Gets Stopped It's been a bad two months for Idenix Pharmaceuticals. First, negative data for its hepatitis drug candidate, valopicitabine; now the FDA has put a stop to all testing of the drug. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
April 26, 2011
Brian Orelli |
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development? |
The Motley Fool
September 11, 2007
Brian Lawler |
Score One for Pharmasset Shares of Pharmasset were up after the company announced impressive results for its Hepatitis C virus drug candidate R7128. Investors should continue to watch closely. |
The Motley Fool
April 25, 2008
Brian Lawler |
Vertex Silences the Critics New clinical study data bodes well for Vertex Pharmaceuticals' lead drug. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
April 30, 2008
Brian Lawler |
ViroPharma: Risky and Exciting Solid lead drug, meet promising pipeline candidate. |
